1
|
Zhu J, Muraoka K, Ohnishi T, Yanaba Y, Ogura M, Nakayama A, Wakihara T, Liu Z, Okubo T. Synthesis and Structural Analysis of High-Silica ERI Zeolite with Spatially-Biased Al Distribution as a Promising NH 3-SCR Catalyst. Adv Sci (Weinh) 2024; 11:e2307674. [PMID: 38308139 PMCID: PMC11005726 DOI: 10.1002/advs.202307674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 01/05/2024] [Indexed: 02/04/2024]
Abstract
Erionite (ERI) zeolite has recently attracted considerable attention for its application prospect in the selective catalytic reduction of NOx with NH3 (NH3-SCR), provided that the high-silica (Si/Al > 5.5) analog with improved hydrothermal stability can be facilely synthesized. In this work, ERI zeolites with different Si/Al ratios (4.6, 6.4, and 9.1) are synthesized through an ultrafast route, and in particular, a high-silica ERI zeolite with a Si/Al ratio of 9.1 is obtained by using faujasite (FAU) as a starting material. The solid-state 29Si MAS NMR spectroscopic study in combination with a computational simulation allows for figuring out the atomic configurations of the Al species in the three ERI zeolites. It is revealed that the ERI zeolite with the highest Si/Al ratio (ERI-9.1, where the number indicates the Si/Al ratio) exhibits a biased Al occupancy at T1 site, which is possibly due to the presence of a higher fraction of the residual potassium cations in the can cages. In contrast, the Al siting in ERI-4.6 and ERI-6.4 proves to be relatively random.
Collapse
Affiliation(s)
- Jie Zhu
- Department of Chemical System EngineeringThe University of Tokyo7‐3‐1 HongoBunkyo‐kuTokyo113‐8656Japan
| | - Koki Muraoka
- Department of Chemical System EngineeringThe University of Tokyo7‐3‐1 HongoBunkyo‐kuTokyo113‐8656Japan
| | - Takeshi Ohnishi
- Institute of Industrial ScienceThe University of Tokyo4‐6‐1 KomabaMeguro‐kuTokyo153‐8505Japan
| | - Yutaka Yanaba
- Institute of Industrial ScienceThe University of Tokyo4‐6‐1 KomabaMeguro‐kuTokyo153‐8505Japan
| | - Masaru Ogura
- Institute of Industrial ScienceThe University of Tokyo4‐6‐1 KomabaMeguro‐kuTokyo153‐8505Japan
| | - Akira Nakayama
- Department of Chemical System EngineeringThe University of Tokyo7‐3‐1 HongoBunkyo‐kuTokyo113‐8656Japan
| | - Toru Wakihara
- Department of Chemical System EngineeringThe University of Tokyo7‐3‐1 HongoBunkyo‐kuTokyo113‐8656Japan
- Institute of Engineering InnovationThe University of Tokyo2‐11‐16 YayoiBunkyo‐kuTokyo113‐8656Japan
| | - Zhendong Liu
- Department of Chemical System EngineeringThe University of Tokyo7‐3‐1 HongoBunkyo‐kuTokyo113‐8656Japan
- Institute of Engineering InnovationThe University of Tokyo2‐11‐16 YayoiBunkyo‐kuTokyo113‐8656Japan
- State Key Laboratory of Chemical EngineeringDepartment of Chemical EngineeringTsinghua UniversityHaidian DistrictBeijing100084China
| | - Tatsuya Okubo
- Department of Chemical System EngineeringThe University of Tokyo7‐3‐1 HongoBunkyo‐kuTokyo113‐8656Japan
| |
Collapse
|
2
|
Kokubo M, Kishi N, Matsuo Y, Ogura M, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Otsu S, Katagiri T, Narabayashi M, Fujishiro S, Iizuka Y, Ozasa H, Hirai T, Mizowaki T. Major Cardiovascular Events after Chemoradiotherapy with or without Durvalumab in Patients with Stage III Non-Small Cell Lung Cancer: Supplementary Analysis. Int J Radiat Oncol Biol Phys 2023; 117:e30-e31. [PMID: 37785096 DOI: 10.1016/j.ijrobp.2023.06.715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) RTOG 0617 showed that cardiac events are relatively common after high-dose thoracic radiotherapy. The aim of this study was to investigate the incidence and risk of major cardiovascular events (MACE) after concurrent chemoradiotherapy (CCRT) with or without durvalumab in patients with stage III non-small cell lung cancer (NSCLC) using the data from a multi-institutional study in Japan. MATERIALS/METHODS Patients who received CCRT for stage III NSCLC between July 2018 and July 2019 were enrolled in a multi-institutional study in Japan. MACE was defined as follows: symptomatic pericardial effusion, acute coronary syndrome, pericarditis, significant arrhythmia, and heart failure. The cumulative incidence of MACE, accounting for death as a competing risk, was calculated. Pre-existing coronary heart disease (CHD) included coronary artery disease, congestive heart failure, peripheral vascular disease, stroke, and extensive coronary artery calcification. The association between patient/treatment-related factors and MACE was assessed by multivariate analysis. RESULTS Among 178 patients with a median follow-up period of 42.5 months, 13 patients developed MACEs. The 3-year cumulative incidence of MACE was 6.9% (95% confidence interval [CI], 4.0-11.9%). Univariate analysis showed that female sex and mean heart dose (MHD) were marginally associated (3-year cumulative incidence, male 5.6% vs. female 12.1%; P = 0.12; MHD ≥ 6.3 Gy 4.8% vs. < 6.3 Gy 9.1%; P = 0.13), and pre-existing CHD was significantly associated with an increased risk of MACE (no CHD 4.3% vs. CHD 16.8%; P = 0.026). Consolidation durvalumab was not associated with an increased risk of MACE (no durvalumab 5.2% vs. durvalumab 7.4%; P = 0.89). Multivariate analysis showed that pre-existing CHD was significantly associated with MACE (hazard ratio, 4.22; 95% CI, 1.30-13.7; P = 0.016). CONCLUSION The incidence of MACE based on the real-world data in Japan was lower than previously reported. Pre-existing CHD was associated with an increased risk of MACE after CCRT in patients with stage III NSCLC, whereas the administration of consolidation durvalumab was not associated with an increased risk of MACE.
Collapse
Affiliation(s)
- M Kokubo
- Department of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan
| | - N Kishi
- Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Y Matsuo
- Department of Radiation Oncology and Image-applied therapy, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - M Ogura
- Department of Radiation Oncology, Kishiwada City Hospital, Kishiwada, Japan
| | - N Araki
- Department of Radiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
| | - K Fujii
- Department of Radiation Oncology, Kurashiki Central Hospital, Kurashiki, Japan
| | - S Okumura
- Department of Radiation Oncology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | - K Nakamatsu
- Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
| | - T Kishi
- Department of Radiation Oncology, Osaka Red Cross Hospital, Osaka, Japan
| | - T Atsuta
- Department of Radiology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
| | - T Sakamoto
- Department of Radiation Oncology, Kyoto Katsura Hospital, Kyoto, Japan
| | - S Otsu
- Department of Radiation Oncology, Kyoto City Hospital, Kyoto, Japan
| | - T Katagiri
- Department of Radiation Oncology, Tenri Hospital, Tenri, Japan
| | - M Narabayashi
- Department of Radiology, Japanese Red Cross Fukui Hospital, Fukui, Japan
| | - S Fujishiro
- Department of Radiation Oncology, Shinko Hospital, Kobe, Japan
| | - Y Iizuka
- Department of Radiation Oncology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
| | - H Ozasa
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Hirai
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Mizowaki
- Department of Radiation Oncology and Image-applied therapy, Kyoto University Graduate School of Medicine, Kyoto, Japan
| |
Collapse
|
3
|
Kishi N, Matsuo Y, Ogura M, Kokubo M, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Otsu S, Katagiri T, Narabayashi M, Fujishiro S, Iizuka Y, Ozasa H, Hirai T, Mizowaki T. Real-World Study of Overall Survival in Patients with Stage III Non-Small Cell Lung Cancer Treated with Chemoradiotherapy with or without Durvalumab and an Exploratory Analysis of Effective Radiation Dose to the Immune Cells. Int J Radiat Oncol Biol Phys 2023; 117:e29-e30. [PMID: 37785070 DOI: 10.1016/j.ijrobp.2023.06.713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To investigate the real-world data on overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy (CCRT) with or without consolidation durvalumab, and to perform an exploratory analysis on effective radiation dose to the immune cells (EDIC). MATERIALS/METHODS In our multi-institutional retrospective study, patients who received CCRT between July 2018 and July 2019 for stage III NSCLC in Japan were investigated. EDIC was estimated using mean lung dose, mean heart dose, body volume, body mean dose, and body weight, as reported in the secondary analysis of RTOG 0617. The cut-off value of EDIC was calculated using the maximally selected log-rank statistics. RESULTS One hundred and seventy-eight patients were eligible for the analysis (136 patients, CCRT with consolidation durvalumab [CCRT+D] cohort; 42 patients, CCRT cohort). The median follow-up period was 42.5 months. Three-year OS rates were 59.8% in the overall cohort: 60.5% in the CCRT+D cohort, and 58.0% in the CCRT cohort with no significant difference (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.45-1.27; P = 0.29). Univariate analysis showed that ECOG-PS, smoking history, histology, EGFR mutational status, gross tumor volume and EDIC were significantly associated with OS. Multivariate analysis showed that ECOG-PS 2, gross tumor volume ≥ 57 cm3 and EDIC ≥ 4.4 Gy were associated with poor OS. Among 21 EGFR-mutated patients, 3 year-OS rates were 64.7% in the CCRT+D cohort and 100% in the CCRT cohort, while 3 year-OS rates were 68.8% and 58.7% among 90 EGFR wild-type patients. Three-year OS rates were 64.6% and 47.6% for EDIC < 4.4 Gy and EDIC ≥ 4.4 Gy in the overall cohort (HR, 1.82; 95% CI, 1.14-2.90; P = 0.015). In the subgroup analysis, 66.3% vs. 44.4% in the CCRT+D cohort (HR, 2.01; 95% CI, 1.17-3.47; P = 0.016), and 59.0% vs. 56.1% in the CCRT cohort (HR, 1.20; 95% CI, 0.48-3.01; P = 0.70), respectively. CONCLUSION Our real-world data in Japan showed that there was no significant difference in OS between the CCRT+D cohort and the CCRT cohort. High EDIC could be a risk for poor OS in patients treated with CCRT and consolidation durvalumab compared with those treated with CCRT.
Collapse
Affiliation(s)
- N Kishi
- Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Y Matsuo
- Department of Radiation Oncology and Image-applied therapy, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - M Ogura
- Department of Radiation Oncology, Kishiwada City Hospital, Kishiwada, Japan
| | - M Kokubo
- Department of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan
| | - N Araki
- Department of Radiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
| | - K Fujii
- Department of Radiation Oncology, Kurashiki Central Hospital, Kurashiki, Japan
| | - S Okumura
- Department of Radiation Oncology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | - K Nakamatsu
- Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
| | - T Kishi
- Department of Radiation Oncology, Osaka Red Cross Hospital, Osaka, Japan
| | - T Atsuta
- Department of Radiology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
| | - T Sakamoto
- Department of Radiation Oncology, Kyoto Katsura Hospital, Kyoto, Japan
| | - S Otsu
- Department of Radiation Oncology, Kyoto City Hospital, Kyoto, Japan
| | - T Katagiri
- Department of Radiation Oncology, Tenri Hospital, Tenri, Japan
| | - M Narabayashi
- Department of Radiology, Japanese Red Cross Fukui Hospital, Fukui, Japan
| | - S Fujishiro
- Department of Radiation Oncology, Shinko Hospital, Kobe, Japan
| | - Y Iizuka
- Department of Radiation Oncology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
| | - H Ozasa
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Hirai
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Mizowaki
- Department of Radiation Oncology and Image-applied therapy, Kyoto University Graduate School of Medicine, Kyoto, Japan
| |
Collapse
|
4
|
Nakayama I, Takahari D, Chin K, Wakatsuki T, Takamatsu M, Yamamoto N, Ogura M, Ooki A, Fukuda K, Osumi H, Fukuoka S, Shinozaki E, Yamaguchi K. Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma. ESMO Open 2023; 8:101582. [PMID: 37348349 PMCID: PMC10485394 DOI: 10.1016/j.esmoop.2023.101582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 05/10/2023] [Accepted: 05/15/2023] [Indexed: 06/24/2023] Open
Abstract
BACKGROUND According to the DESTINY-Breast04 trial, treating patients with breast cancer and low human epidermal growth factor receptor 2 expressions (HER2-low) varies from that of those with no HER2 expression. However, it is interesting to know if HER2-low indicates for anti-HER2 therapy in the gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Hence we conducted this study to assess the incidence, clinicopathological features, and treatment outcomes of patients with HER2-low G/GEJ adenocarcinoma. PATIENTS AND METHODS This was a single-center, retrospective observational study. Patients with previously untreated G/GEJ adenocarcinoma were classified based on their HER2 status using immunohistochemistry (IHC) with or without in situ hybridization (ISH) as follows: HER2 negative (IHC 0), HER2-low (IHC 1+ or 2+/ISH-), and HER2-positive (IHC2+/ISH+ or 3+). RESULTS In total, 734 patients with G/GEJ adenocarcinoma were divided into three groups (HER2-negative, n = 410; HER2-low, n = 154, and HER2-positive, n = 170). The intestinal-type histology, peritoneal metastasis, and higher serum carcinoembryonic antigen (CEA) levels differed significantly among patients with negative, low, and positive HER2 statuses: intestinal-type histology (21.0%, 44.2%, and 59.8%, respectively), peritoneal metastasis (56.3%, 44.8%, and 21.8%, respectively), and higher serum CEA level (32.2%, 41.6%, and 56.5%, respectively). Improved survival was observed in the HER2-positive group than in the HER2-negative G/GEJ adenocarcinoma group [hazard ratio (HR) = 0.73, 95% confidence interval (CI) 0.59-0.89; P = 0.002]. However, the prognoses of the HER2-low and HER2-negative groups were similar (HR = 1.01, 95% CI 0.82-1.23; P = 0.843). CONCLUSIONS Patients with HER2-low G/GEJ adenocarcinoma exhibited intermediate and distinct characteristics than those in the HER2-negative group. Similarly, the HER2-low group's prognosis was worse than that of the HER2-positive group. Therefore developing novel therapeutic strategies targeting HER2-low G/GEJ adenocarcinoma is required.
Collapse
Affiliation(s)
- I Nakayama
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo
| | - D Takahari
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo.
| | - K Chin
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo
| | - T Wakatsuki
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo
| | - M Takamatsu
- Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, , Tokyo, Japan
| | - N Yamamoto
- Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, , Tokyo, Japan
| | - M Ogura
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo
| | - A Ooki
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo
| | - K Fukuda
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo
| | - H Osumi
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo
| | - S Fukuoka
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo
| | - E Shinozaki
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo
| | - K Yamaguchi
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo
| |
Collapse
|
5
|
Moteki T, Sei T, Ogura M. Synthesis of titanosilicate nanoparticles with high titanium content from a silsesquioxane-based precursor for a model epoxidation reaction. Nanoscale 2023. [PMID: 37200004 DOI: 10.1039/d3nr01385e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
In conventional hydrothermal synthesis of porous titanosilicate materials, undesired aggregation of TiO2 species during the synthesis limits the content of active four-coordinated Ti to an Si/Ti ratio of about 40. Aiming to increase the content of active four-coordinated Ti species, we report a bottom-up synthesis of titanosilicate nanoparticles using a Ti-incorporated cubic silsesquioxane cage as a precursor, which allowed incorporating a larger number of four-coordinated Ti species in the silica matrix to reach an Si/Ti ratio of 19. Even at this relatively high Ti concentration, the catalytic activity in the epoxidation of cyclohexene over the titanosilicate nanoparticles was comparable to that of a conventional reference Ti catalyst, Ti-MCM-41, with an Si/Ti ratio of 60. The activity per Ti site was not affected by the Ti content in the nanoparticles, suggesting that well dispersed and stabilized Ti species were the active sites.
Collapse
Affiliation(s)
- Takahiko Moteki
- Materials and Environmental Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8505, Japan.
| | - Tomohiro Sei
- Materials and Environmental Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8505, Japan.
| | - Masaru Ogura
- Materials and Environmental Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8505, Japan.
| |
Collapse
|
6
|
Tsunoda S, Shimizu S, Suzuki Y, Tsunoda A, Yamada R, Shimose R, Kawabata M, Ogura M, Matsunaga A. Longitudinal changes in life-space mobility and the factors influencing it among chronic community-dwelling post-stroke patients. Disabil Rehabil 2022; 44:7872-7876. [PMID: 34894964 DOI: 10.1080/09638288.2021.2001054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
PURPOSE To identify longitudinal changes in life-space mobility and the factors influencing it among chronic, stable post-stroke patients. MATERIALS AND METHODS This prospective study included Japanese post-stroke patients who received day-care rehabilitation services and could undergo three life-space mobility assessments (at baseline, 12, and 24 months) for over 2 years, using the Life-Space Assessment (LSA) tool. Physical function, cognitive function, and activities of daily living were assessed by self-selected comfortable gait speed, Mini-Mental State Examination (MMSE), and Functional Independence Measure Motor subscale (FIM motor) scores, respectively, in addition to age, sex, time from onset, stroke type, and comorbidities. A multivariable linear mixed-effects model was used to examine the longitudinal changes in LSA scores and associated factors. RESULTS A total of 89 participants were enrolled. At baseline, the median age was 74 years, 33% were women, and median time from onset was 75 months. The LSA scores significantly declined over the two-year period. In the multivariate linear mixed-effects model adjusted for clinical characteristics, comfortable gait speed and age were significantly associated with changes in the LSA score, independent of FIM motor scores and MMSE scores. CONCLUSIONS Life-space mobility may persistently decline, and gait function may be a determinant influencing these changes in community-dwelling chronic post-stroke patients.Implications for RehabilitationLimited life-space mobility leads to less frequent participation in social activities and an increased risk of adverse health outcomes such as hospitalization.Changes in life-space mobility should be considered in the rehabilitation care plan for chronic post-stroke patients.Life-space mobility may decline persistently in stable post-stroke patients, even if they have periodically received day-care rehabilitation services.Since gait speed is a predominant factor affecting life-space mobility, regular assessment of gait function and appropriate strategies are needed to prevent deterioration of gait speed in chronic post-stroke patients.
Collapse
Affiliation(s)
- S Tsunoda
- Department of Rehabilitation, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan.,Department of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan
| | - S Shimizu
- Department of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.,Department of Rehabilitation, Kitasato University School of Allied Health Sciences, Sagamihara, Japan
| | - Y Suzuki
- Department of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan
| | - A Tsunoda
- Department of Rehabilitation, Chigasaki Tokushukai Hospital, Chigasaki, Japan
| | - R Yamada
- Department of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan
| | - R Shimose
- Department of Physical Therapy, Okayama Healthcare Professional University, Okayama, Japan
| | - M Kawabata
- Department of Rehabilitation, Kitasato University School of Allied Health Sciences, Sagamihara, Japan
| | - M Ogura
- Department of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.,Department of Rehabilitation, Kitasato University School of Allied Health Sciences, Sagamihara, Japan
| | - A Matsunaga
- Department of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.,Department of Rehabilitation, Kitasato University School of Allied Health Sciences, Sagamihara, Japan
| |
Collapse
|
7
|
Funabashi S, Kataoka Y, Hori M, Ogura M, Doi T, Noguchi T, Shiba M. The effect of achieving LDL-C <1.8 mmol/L to prevent the first atherosclerotic cardiovascular events in the primary prevention settings of severe heterozygous familial hypercholesterolemia. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
The International Atherosclerosis Society (IAS) has proposed “severe familial hypercholesterolemia” (FH) as a phenotype with the highest cardiovascular risk. LDL-C <2.5 mmol/l is a recommended therapeutic goal for the primary prevention settings of severe FH. However, given that ESC guidelines recommends LDL-C <1.8 mmol/l in FH patients, this stricter goal may be better to prevent the first atherosclerotic cardiovascular disease (ASCVD) in severe FH patients.
Purpose
To determine whether achieving LDL-C<1.8 mg/dl is more beneficial to reduce the first ASCVD events.
Methods
A total of 148 severe FH subjects without any history of ASCVD were analyzed. Severe FH was defined as untreated LDL-C >10.3 mmol/l, LDL-C >8.0 mmol/l+ 1 high-risk feature, LDL-C >4.9 mmol/l + 2 high-risk features according to IAS proposed statement. The occurrence of ASCVD (all-cause death, CAD, ischemic stroke and lower extremity artery disease (LEAD)) were compared in those with on-treatment LDL-C < and ≥1.8 mmol/L.
Results
10.1% (=15/148) of study subjects achieved on-treatment LDL-C <1.8 mmol/l. They were more likely to receive PCSK9 inhibitor (15.0 vs. 66.7%, p<0.01), whereas there was no significant difference in FH-related physical characteristics (tendon xanthomas: 72.2 vs. 93.3%, p=0.12) and causative genotypes (LDLR: 68.4 vs. 66.7%, p=1.00, PCSK9: 8.3 vs. 6.7%, p=1.00, LDLR/PCSK9: 3.8 vs. 6.7%, p=0.48), untreated LDL-C (7.3±1.7 vs. 7.9±1.8 mmol/l, p=0.22) and lipoprotein(a) (23 [11–42] vs. 25 [15–70] mg/dl, p=0.41) levels between two groups. During the observational period (median=7.0 years), severe FH achieving on-treatment LDL-C <1.8 mmol/l was associated with a lower likelihood of experiencing ASCVD events (Figure 1). Of note, any cardiovascular events did not occur in severe FH who achieved on-treatment LDL-C <1.8 mmol/l. In those with on-treatment LDL ≥1.8 mmol/L, CAD (76.5%=26/34) was more dominant component of ASCVD, followed by ischemic stroke (17.6%=6/34) and LEAD (5.9%=2/34).
Conclusions
A significantly lower frequency of ASCVD was observed in severe FH who achieved LDL-C <1.8 mmol/L in the primary prevention settings. Given that only 10.1% of severe FH patients achieved LDL-C <1.8 mmol/l, more actions are required to motivate physicians for further intensified management of LDL-C in severe FH patients in the primary prevention settings.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S Funabashi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine , Osaka , Japan
| | - Y Kataoka
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine , Osaka , Japan
| | - M Hori
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology , Osaka , Japan
| | - M Ogura
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology , Osaka , Japan
| | - T Doi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine , Osaka , Japan
| | - T Noguchi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine , Osaka , Japan
| | - M Shiba
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology , Osaka , Japan
| |
Collapse
|
8
|
Ge J, Ohata Y, Fukuda A, Tokumoto Y, Ohnishi T, Moteki T, Ogura M. Synthesis of Carbon Nanoparticles with Cobalt-Rich Shell via Pyrolysis of Zn-ZIF@Co/Zn-ZIF: Relevance of Co(III) Precursors. Inorg Chem 2022; 61:7859-7868. [PMID: 35546085 DOI: 10.1021/acs.inorgchem.2c00452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
To the best of our knowledge, this is the first report on the rapid one-pot synthesis of a unique core-shell-structured zeolitic imidazolate framework (ZIF) using Co(III) and Zn(II) precursors. The key to obtaining this unique structure is the use of a Co(III) precursor as the starting material. Transmission electron microscopy (TEM) reveals that Co was present within a 30-nm-thick shell layer of the ZIF material. Thermal decomposition of the ZIF material affords core-shell-structured carbon nanoparticles that have Co on the external surface of the carbon grain. We have previously demonstrated that this carbonaceous material obtained by thermal decomposition exhibited high performance as an adsorbent for nitric oxide, even in the presence of excess oxygen and water vapor, and therefore, it was a suitable material for NOx elimination at low temperatures. The growth mechanism of the synthesized ZIF particles and the differences between synthesized ZIF and conventional Co(II)-ZIF-67 are discussed. The reactivity of the Co(III) precursor is much lower than that of the Co(II) species, leading to slower precipitation of Co(III) than that of Zn(II), thus forming the core-shell structure.
Collapse
Affiliation(s)
- Jiachen Ge
- Institute of Industrial Science, The University of Tokyo, Komaba 4-6-1, Meguro, Tokyo 153-8505, Japan
| | - Yusuke Ohata
- Institute of Industrial Science, The University of Tokyo, Komaba 4-6-1, Meguro, Tokyo 153-8505, Japan
| | - Atsushi Fukuda
- Institute of Industrial Science, The University of Tokyo, Komaba 4-6-1, Meguro, Tokyo 153-8505, Japan
| | - Yuki Tokumoto
- Institute of Industrial Science, The University of Tokyo, Komaba 4-6-1, Meguro, Tokyo 153-8505, Japan
| | - Takeshi Ohnishi
- Institute of Industrial Science, The University of Tokyo, Komaba 4-6-1, Meguro, Tokyo 153-8505, Japan
| | - Takahiko Moteki
- Institute of Industrial Science, The University of Tokyo, Komaba 4-6-1, Meguro, Tokyo 153-8505, Japan
| | - Masaru Ogura
- Institute of Industrial Science, The University of Tokyo, Komaba 4-6-1, Meguro, Tokyo 153-8505, Japan
| |
Collapse
|
9
|
Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Otsu S, Katagiri T, Narabayashi M, Fujishiro S, Iizuka Y, Ozasa H, Mizowaki T. PO-1279 PFS and recurrence patterns after CCRT with durvalumab for stage III and recurrent NSCLC. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03243-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Li H, Sakai T, Tanaka A, Ogura M, Lee C, Yamaguchi S, Imazato S. Interpretable AI Explores Effective Components of CAD/CAM Resin Composites. J Dent Res 2022; 101:1363-1371. [DOI: 10.1177/00220345221089251] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
High flexural strength of computer-aided manufacturing resin composite blocks (CAD/CAM RCBs) are required in clinical scenarios. However, the conventional in vitro approach of modifying materials’ composition by trial and error was not efficient to explore the effective components that contribute to the flexural strength. Machine learning (ML) is a powerful tool to achieve the above goals. Therefore, the aim of this study was to develop ML models to predict the flexural strength of CAD/CAM RCBs and explore the components that affect flexural strength as the first step. The composition of 12 commercially available products and flexural strength were collected from the manufacturers and literature. The initial data consisted of 16 attributes and 12 samples. Considering that the input data for each sample were recognized as a multidimensional vector, a fluctuation range of 0.1 was proposed for each vector and the number of samples was augmented to 120. Regression algorithms—that is, random forest (RF), extra trees, gradient boosting decision tree, light gradient boosting machine, and extreme gradient boosting—were used to develop 5 ML models to predict flexural strength. An exhaustive search and feature importance analysis were conducted to analyze the effective components that affected flexural strength. The R2 values for each model were 0.947, 0.997, 0.998, 0.983, and 0.927, respectively. The relative errors of all the algorithms were within 15%. Among the high predicted flexural strength group in the exhaustive search, urethane dimethacrylate was contained in all compositions. Filler content and triethylene glycol dimethacrylate were the top 2 features predicted by all models in the feature importance analysis. ZrSiO4 was the third important feature for all models, except the RF model. The ML models established in this study successfully predicted the flexural strength of CAD/CAM RCBs and identified the effective components that affected flexural strength based on the available data set.
Collapse
Affiliation(s)
- H. Li
- Department of Biomaterials Science, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| | - T. Sakai
- Department of Biomaterials Science, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
- Department of Fixed Prosthodontics, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| | - A. Tanaka
- Department of Biomaterials Science, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| | - M. Ogura
- Department of Biomaterials Science, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| | - C. Lee
- Department of Biomaterials Science, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| | - S. Yamaguchi
- Department of Biomaterials Science, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| | - S. Imazato
- Department of Biomaterials Science, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| |
Collapse
|
11
|
Ge J, Ohata Y, Ohnishi T, Moteki T, Ogura M. Highly Dispersed Co/Zn-Doped Zeolitic Imidazolate Framework-Derived Carbon Nanoparticles with High NO Adsorption Capacity at Low Operating Temperature. Ind Eng Chem Res 2022. [DOI: 10.1021/acs.iecr.1c04511] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Jiachen Ge
- Institute of Industrial Science, The University of Tokyo, Komaba, Meguro, Tokyo 153-8505, Japan
| | - Yusuke Ohata
- Institute of Industrial Science, The University of Tokyo, Komaba, Meguro, Tokyo 153-8505, Japan
- Elements Strategy Initiative for Catalysts and Batteries, Kyoto University, Katsura, Kyoto 615-8520, Japan
| | - Takeshi Ohnishi
- Institute of Industrial Science, The University of Tokyo, Komaba, Meguro, Tokyo 153-8505, Japan
| | - Takahiko Moteki
- Institute of Industrial Science, The University of Tokyo, Komaba, Meguro, Tokyo 153-8505, Japan
- Elements Strategy Initiative for Catalysts and Batteries, Kyoto University, Katsura, Kyoto 615-8520, Japan
| | - Masaru Ogura
- Institute of Industrial Science, The University of Tokyo, Komaba, Meguro, Tokyo 153-8505, Japan
- Elements Strategy Initiative for Catalysts and Batteries, Kyoto University, Katsura, Kyoto 615-8520, Japan
| |
Collapse
|
12
|
Sugisaki T, Aoyama T, Kawakami K, Yokokawa T, Kobayashi K, Suzuki W, Ogura M, Ichimura T, Chin K, Yamaguchi K, Hanaoka S, Hayashi H, Yamaguchi M. Correlation between magnesium pre-loading and cisplatin-induced nephrotoxicity in 5-fluorouracil/cisplatin combination therapy for esophageal cancer. Pharmazie 2022; 77:85-88. [PMID: 35209969 DOI: 10.1691/ph.2022.11038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
The use of cisplatin may cause nephrotoxicity in patients. Hydration solutions supplemented with magnesium could reduce cisplatin-induced nephrotoxicity. In this study, we evaluated the preventive effect of magnesium pre-loading on cisplatin-induced nephrotoxicity in patients with esophageal cancer. We retrospectively evaluated the prevalence of, and risk factors for, nephrotoxicity in 160 patients with esophageal cancer treated with the 5-fluorouracil/cisplatin regimen from 2014 to 2016 with and without magnesium supplementation. Significant differences were observed between the magnesium and non-magnesium groups in terms of frequency of estimated creatinine clearance of grade 2 or higher that was at 4% (n = 3) and 13% (n = 10) (p = 0.027), respectively. The logistic regression analysis revealed that eCcr of grade 2 or higher was significantly associated with the non-magnesium regimen (odds ratio (OR), 4.175; 95% confidence interval (CI) = 1.061-16.430; p = 0.041) and age ≥ 65 years (OR, 13.951; 95% CI = 1.723-112.974; p = 0.014). This study suggests that 20 mEq magnesium pre-loading significantly reduces the prevalence of cisplatin-induced nephrotoxicity. Furthermore, when cisplatin is administered to individuals older than 64 years, a close observation for the onset of cisplatin-induced nephrotoxicity is crucial.
Collapse
Affiliation(s)
- T Sugisaki
- Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - T Aoyama
- Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo;,
| | - K Kawakami
- Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - T Yokokawa
- Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - K Kobayashi
- Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - W Suzuki
- Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - M Ogura
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - T Ichimura
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - K Chin
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - K Yamaguchi
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - S Hanaoka
- Department of Pharmacotherapy, School of Pharmacy, Nihon University, Chiba, Japan
| | - H Hayashi
- Department of Pharmacotherapy, School of Pharmacy, Nihon University, Chiba, Japan
| | - M Yamaguchi
- Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| |
Collapse
|
13
|
Funabashi S, Kataoka Y, Ogura M, Kuyama N, Otsuka F, Asaumi Y, Noguchi T. Characterization of cholesterol efflux capacity in diabetic and non-diabetic patients with coronary artery disease: comparison between acute coronary syndrome and stable coronary artery disease. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Type 2 diabetic patients more likely exhibit a lower high-density lipoprotein (HDL) level. Given a greater glycation and oxidative stress in diabetic subjects, these atherogenic characteristics could cause dysfunctional HDL including a reduced cholesterol efflux capacity (CEC), which may account for an increased risk of diabetic macrovascular disease including acute coronary syndrome (ACS). However, it remains to be fully elucidated characteristics of HDL-mediated CEC in type 2 diabetic patients, in association with clinical presentation of coronary artery disease (CAD).
Purpose
To characterize CEC in CAD subjects with type 2 diabetes mellitus.
Methods
The current study prospectively analyzed 87 statin-naive patients with CAD. CEC was measured by using the collected apolipoprotein B-depleted serum. Liquid scintillation counting (Perkin-Elmer Analytical Sciences, MA, US) was used to quantify the efflux of radioactive cholesterol from J774 cells. Clinical characteristics and CEC were compared in diabetic and non-diabetic subjects.
Results
The averaged HbA1c in diabetic patients was 6.7±1.2, and 66.7% of them achieved HbA1c <7.0%. Diabetic subjects more likely exhibited a history of hypertension and dyslipidemia, and multi-vessel disease (Table). Moreover, a lower CEC level was observed in diabetic patients, accompanied by a lower HDL-C and apolipoprotein A-I levels with a higher level of triglyceride (Table). HDL-C (r=0.62, p-value<0.01) and Apolipoprotein A-I (r=0.70, p-value <0.01) were associated with CEC, whereas there was no significant difference in CEC between subjects with HbA1c <7.0% vs. ≥7.0% (0.74±0.07 vs. 0.78±0.08, p=0.22). On multivariate analysis, type 2 diabetes mellitus was an independent contributor to CEC <0.79 (median) (HR=2.75, 95% CI: 1.11–6.82, p=0.03). Interestingly in particular, CEC was substantially lower in diabetic patients with ACS compared to those with stable CAD (Figure). By contrast, clinical presentation of CAD did not affect CEC in non-diabetic subjects (Figure).
Conclusions
A lower CEC level was observed in subjects with type 2 diabetes mellitus. In particular, this HDL functionality was profoundly diminished in those presenting ACS. Our findings suggest functionality of HDL as a potential therapeutic target in diabetic patients experiencing ACS.
Funding Acknowledgement
Type of funding sources: None. Table 1Figure 1
Collapse
Affiliation(s)
- S Funabashi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - Y Kataoka
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - M Ogura
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - N Kuyama
- Kumamoto University Hospital, Cardiovascular Medicine, Kumamoto, Japan
| | - F Otsuka
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - Y Asaumi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - T Noguchi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| |
Collapse
|
14
|
Tada H, Hori M, Matsuki K, Ogura M, Nohara A, Kawashiri M, Hadara-Shiba M. Achilles tendon thickness assessed by X-ray predicting a pathogenic mutation in familial hypercholesterolemia gene. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The 2017 Japan Atherosclerosis Society (JAS) familial hypercholesterolemia (FH) criteria adopts a cut off value of ≥9 mm of Achilles tendon thickness (ATT) detected by X-ray as one of the three key items. This threshold was determined based on an old data assessing ATT of 36 non-FH individuals published in 1977. Although the specificity of this clinical criteria is extremely high due to a strict threshold, there are substantial number of patients with FH whose ATT <9 mm. We aimed to determine a cut off value of ATT detected by X-ray to differentiate FH and non-FH based on genetic diagnosis.
Methods
The individuals (male/female = 486/501) with full assessments of genetic analyses for FH-genes (LDLR, and PCSK9), serum lipids, and ATT detected by X-ray at Kanazawa University Hospital and National Cerebral and Cardiovascular Center Research Institute were included in this study. Receiver operating characteristic (ROC) analyses were performed to determine a better cut off point of ATT predicting a pathogenic mutation of FH.
Results
ROC analyses revealed the best cut off values of ATT as 7.6 mm for male, and 7.0 mm for female with the sensitivities and specificities of 0.83 and 0.83 for male and 0.86 and 0.85 for female, respectively. If the thresholds of ATT of 8.0/7.5 mm and 7.5/7.0 mm were applied to diagnose of male/female FH, the sensitivities/specificities predicting a pathogenic mutation of FH by the 2017 JAS FH clinical criteria would be 0.82/0.90 and 0.85/0.88, respectively.
Conclusions
These results suggest that the cut-off value of ATT detected by X-ray is obviously lower than 9.0 mm adopted by the 2017 JAS FH clinical criteria.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | - M Hori
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - K Matsuki
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - M Ogura
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - A Nohara
- Ishikawa Prefectural Central Hospital, Kanazawa, Japan
| | | | | |
Collapse
|
15
|
Shimozaki K, Nakayama I, Takahari D, Osumi H, Kamiimabeppu D, Wakatsuki T, Oki A, Ogura M, Shinozaki E, Chin K, Yamaguchi K. 1426P The utility of the prognostic index for practicing the continuum of care in advanced gastric cancer: The suitability assessment and modification of the JCOG prognostic index in real-world data. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
16
|
Nakayama I, Takahari D, Shimozaki K, Chin K, Wakatsuki T, Oki A, Kamiimabeppu D, Osumi H, Ogura M, Shinozaki E, Yamaguchi K. 1391P Clinical progress in inoperable or recurrent advanced gastric cancer treatment from 1,004 single institute experiences between 2007 and 2018. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
17
|
Moteki T, Tominaga N, Tsunoji N, Yokoi T, Ogura M. Impact of the Zeolite Cage Structure on Product Selectivity in CO-assisted Direct Partial Oxidation of Methane over Rh Supported AEI-, CHA-, and AFX-type Zeolites. CHEM LETT 2021. [DOI: 10.1246/cl.210250] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Takahiko Moteki
- Institute of Industrial Science, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan
| | - Naoto Tominaga
- Institute of Industrial Science, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan
| | - Nao Tsunoji
- Graduate School of Advanced Science and Engineering, Hiroshima University, Higashi-hiroshima, Hiroshima 739-8527, Japan
| | - Toshiyuki Yokoi
- Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Kanagawa 226-8503, Japan
| | - Masaru Ogura
- Institute of Industrial Science, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan
| |
Collapse
|
18
|
Nagahara M, Krishnamachari B, Ogura M, Ortega A, Tanaka Y, Ushifusa Y, Valente TW. Control, intervention, and behavioral economics over human social networks against COVID-19. Adv Robot 2021. [DOI: 10.1080/01691864.2021.1928553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- M. Nagahara
- Institute of Environmental Science and Technology, The University of Kitakyushu, Kitakyushu, Japan
| | - B. Krishnamachari
- Department of Electrical and Computer Engineering, University of Southern California, Los Angeles, CA, USA
| | - M. Ogura
- Graduate School of Information Science and Technology, Osaka University, Osaka, Japan
| | - A. Ortega
- Department of Electrical and Computer Engineering, University of Southern California, Los Angeles, CA, USA
| | - Y. Tanaka
- Department of Electrical Engineering and Computer Science, Tokyo University of Agriculture and Technology, Tokyo, Japan
| | - Y. Ushifusa
- Faculty of Economics and Business Administration, The University of Kitakyushu, Kitakyushu, Japan
| | - T. W. Valente
- Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA
| |
Collapse
|
19
|
Ohata Y, Ohnishi T, Moteki T, Ogura M. High NH 3-SCR reaction rate with low dependence on O 2 partial pressure over Al-rich Cu-*BEA zeolite. RSC Adv 2021; 11:10381-10384. [PMID: 35423523 PMCID: PMC8695709 DOI: 10.1039/d1ra00943e] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Accepted: 03/05/2021] [Indexed: 11/21/2022] Open
Abstract
Dependence of NH3-SCR reaction rate on O2 partial pressure was investigated at 473 K over Cu ion-exchanged MOR, MFI, CHA and *BEA zeolites with varying “Cu density in micropores”. Among the zeolites, Cu–*BEA zeolite demonstrated promising potential as an effective catalyst for NH3-SCR over a wide range of O2 partial pressure. It was revealed that Al-rich Cu–*BEA zeolite exhibit high reaction rate for NH3-SCR at 473 K in low PO2 reaction condition.![]()
Collapse
Affiliation(s)
- Yusuke Ohata
- Institute of Industrial Science, The University of Tokyo Komaba, Meguro Tokyo 153-8505 Japan
| | - Takeshi Ohnishi
- Institute of Industrial Science, The University of Tokyo Komaba, Meguro Tokyo 153-8505 Japan
| | - Takahiko Moteki
- Institute of Industrial Science, The University of Tokyo Komaba, Meguro Tokyo 153-8505 Japan .,Elements Strategy Initiative for Catalysts and Batteries, Kyoto University Katsura Kyoto 615-8520 Japan
| | - Masaru Ogura
- Institute of Industrial Science, The University of Tokyo Komaba, Meguro Tokyo 153-8505 Japan .,Elements Strategy Initiative for Catalysts and Batteries, Kyoto University Katsura Kyoto 615-8520 Japan
| |
Collapse
|
20
|
Zhao P, Boekfa B, Shimizu KI, Ogura M, Ehara M. Selective catalytic reduction of NO with NH 3 over Cu-exchanged CHA, GME, and AFX zeolites: a density functional theory study. Catal Sci Technol 2021. [DOI: 10.1039/d0cy02342f] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Density functional theory calculations have been applied to study the selectivity caused by the cage size during the selective catalytic reduction of NO by NH3 over the Cu-exchanged zeolites with cha, gme, and aft cages.
Collapse
Affiliation(s)
- Pei Zhao
- Research Center for Computational Science
- Institute for Molecular Science
- Okazaki
- Japan
- Element Strategy Initiative for Catalysts and Batteries (ESICB)
| | - Bundet Boekfa
- Department of Chemistry
- Faculty of Liberal Arts and Science
- Kasetsart University, Kamphaengsaen Campus
- Thailand
| | - Ken-ichi Shimizu
- Element Strategy Initiative for Catalysts and Batteries (ESICB)
- Kyoto University
- Kyoto 615-8245
- Japan
- Institute for Catalysis
| | - Masaru Ogura
- Element Strategy Initiative for Catalysts and Batteries (ESICB)
- Kyoto University
- Kyoto 615-8245
- Japan
- Institute of Industrial Science
| | - Masahiro Ehara
- Research Center for Computational Science
- Institute for Molecular Science
- Okazaki
- Japan
- Element Strategy Initiative for Catalysts and Batteries (ESICB)
| |
Collapse
|
21
|
Liu C, Kubota H, Amada T, Toyao T, Maeno Z, Ogura M, Nakazawa N, Inagaki S, Kubota Y, Shimizu KI. Selective catalytic reduction of NO over Cu-AFX zeolites: mechanistic insights from in situ/ operando spectroscopic and DFT studies. Catal Sci Technol 2021. [DOI: 10.1039/d1cy00282a] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
In situ/operando spectroscopic experiments and DFT calculations unravel the redox mechanism of NH3-SCR over Cu-AFX zeolites.
Collapse
Affiliation(s)
- Chong Liu
- State Key Laboratory of Structural Chemistry
- Fujian Institute of Research on the Structure of Matter
- Chinese Academy of Sciences
- Fuzhou
- China
| | - Hiroe Kubota
- Institute for Catalysis
- Hokkaido University
- Sapporo 001-0021
- Japan
| | - Takehiro Amada
- Institute for Catalysis
- Hokkaido University
- Sapporo 001-0021
- Japan
| | - Takashi Toyao
- Institute for Catalysis
- Hokkaido University
- Sapporo 001-0021
- Japan
- Elements Strategy Initiative for Catalysts and Batteries
| | - Zen Maeno
- Institute for Catalysis
- Hokkaido University
- Sapporo 001-0021
- Japan
| | - Masaru Ogura
- Elements Strategy Initiative for Catalysts and Batteries
- Kyoto University
- Kyoto 615-8520
- Japan
- Institute of Industrial Science
| | - Naoto Nakazawa
- Division of Materials Science and Chemical Engineering
- Yokohama National University
- Yokohama 240-8501
- Japan
| | - Satoshi Inagaki
- Division of Materials Science and Chemical Engineering
- Yokohama National University
- Yokohama 240-8501
- Japan
| | - Yoshihiro Kubota
- Division of Materials Science and Chemical Engineering
- Yokohama National University
- Yokohama 240-8501
- Japan
| | - Ken-ichi Shimizu
- Institute for Catalysis
- Hokkaido University
- Sapporo 001-0021
- Japan
- Elements Strategy Initiative for Catalysts and Batteries
| |
Collapse
|
22
|
Ohata Y, Kubota H, Toyao T, Shimizu KI, Ohnishi T, Moteki T, Ogura M. Kinetic and spectroscopic insights into the behaviour of Cu active site for NH 3-SCR over zeolites with several topologies. Catal Sci Technol 2021. [DOI: 10.1039/d0cy01838d] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Zeolite topology has a great effect on the dependence of NH3-SCR rates over Cu–zeolites at 473 K on Cu density. It is revealed by the time-resolved UV-vis measurements that zeolites mainly affect the oxidation property of Cu ion by O2.
Collapse
Affiliation(s)
- Yusuke Ohata
- Institute of Industrial Science
- The University of Tokyo
- Tokyo 153-8505
- Japan
| | - Hiroe Kubota
- Institute for Catalysis
- Hokkaido University
- Sapporo 001-0021
- Japan
| | - Takashi Toyao
- Institute for Catalysis
- Hokkaido University
- Sapporo 001-0021
- Japan
- Elements Strategy Initiative for Catalysts and Batteries
| | - Ken-ichi Shimizu
- Institute for Catalysis
- Hokkaido University
- Sapporo 001-0021
- Japan
- Elements Strategy Initiative for Catalysts and Batteries
| | - Takeshi Ohnishi
- Institute of Industrial Science
- The University of Tokyo
- Tokyo 153-8505
- Japan
| | - Takahiko Moteki
- Institute of Industrial Science
- The University of Tokyo
- Tokyo 153-8505
- Japan
- Elements Strategy Initiative for Catalysts and Batteries
| | - Masaru Ogura
- Institute of Industrial Science
- The University of Tokyo
- Tokyo 153-8505
- Japan
- Elements Strategy Initiative for Catalysts and Batteries
| |
Collapse
|
23
|
Ogura M, Fujita T, Katayama Y, Harada-Shiba M. High lysophosphatidylcholine and low phosphatidylcholine concentrations in HDL phospholipids are associated with atherosclerosis in relation to decreased cholesterol efflux capacity. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
24
|
Funabashi S, Kataoka Y, Hori M, Ogura M, Matsuki K, Doi T, Noguchi T, Harada-Shiba M. Lp (a) >50 mg/dl predicts atherosclerotic cardiovascular events in patients with heterozygous familial hypercholesterolemia who achieved LDL-C <2.6 mmol/l. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Lipoprotein (a) [Lp (a)] is a plasma lipoprotein which exhibits atherogenic properties. Lp(a) ≥50 mg/dl has been recently shown to associate with a risk of atherosclerotic cardiovascular diseases (ASCVD) in patients with heterozygous familial hypercholesterolemia (HeFH). While current guideline recommends lowering LDL-C as a first-line therapeutic approach in HeFH subjects, it remains to be fully determined whether an elevated level of Lp(a) confers additional ASCVD risks in HeFH patients who achieved a lower LDL-C level.
Purpose
To investigate cardiovascular outcomes in HeFH subjects with a lower LDL-C but an elevated Lp(a) levels.
Methods
182 HeFH patients with on-treatment LDL-C <2.6 mmol/l under lipid-lowering therapies were analyzed. Clinical characteristics and MACE (= a composite of all-cause death, ACS, stroke, PAD and coronary revascularization) were compared in HeFH subjects with Lp(a) ≥ vs. <50 mg/dl.
Results
The averaged LDL-C and Lp (a) levels were 1.9 mmol/l and 26.8 mg/dl, respectively. 19.2% of study subjects exhibited Lp(a)≥50 mg/dl. HeFH patients with Lp(a) ≥50 mg/dl were more likely to be older and have a history of hypertension, but these comparisons did not meet statistical significance. There was no significant difference in on-treatment LDL-C, HDL-C and Triglyceride level (Table). However, during the observational period (median=4.7 years), there was a 2.7-fold (95% CI, 1.41–5.02; p=0.004) greater likelihood of experiencing MACE in subjects with Lp(a) ≥50 mg/dl (picture). Even after adjusting clinical demographics, Lp(a) ≥50 mg/dl remained an independent predictor for the occurrence of MACE (hazard ratio=2.53, 95% CI: 1.29–4.82, p<0.001).
Conclusions
Despite achieving on-treatment LDL-C <2.6 mmol/l, an elevated risk of MACE was observed in HeFH patients with Lp(a) ≥50 mg/dl. Our findings suggest an increased level of Lp(a) as a risk stratification marker and a potential therapeutic target in patients with HeFH.
Clinical outcome
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- S Funabashi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - Y Kataoka
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - M Hori
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - M Ogura
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - K Matsuki
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - T Doi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - T Noguchi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - M Harada-Shiba
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| |
Collapse
|
25
|
Funabashi S, Kataoka Y, Hori M, Ogura M, Matsuki K, Doi T, Noguchi T, Harada-Shiba M. Prevalence, clinical characteristics and prognosis of intracranial artery atherosclerosis in heterozygous familial hypercholesterolemia: insights from magnetic resonance angiography imaging analysis. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Heterozygous familial hypercholesterolemia (HeFH) exhibits substantially atherogenic substrate which involves coronary and peripheral arteries. Whether atherosclerosis in HeFH propagates to intracranial arteries causing stroke remains to be determined.
Purpose
To characterize intracranial artery stenosis (IAS) in subjects with HeFH.
Methods
148 HeFH subjects who underwent MRI/MRA imaging to evaluate intracranial arteries were analyzed. IAS was defined as the presence of stenosis with its % diameter stenosis ≥25%. Clinical demographics and cardiovascular events (all-cause death, ACS, stroke and PAD) were compared in those with and without IAS.
Results
IAS was observed in 24.3% (=36/148) of study subjects. It was more frequently located at middle cerebral artery (30.6%=11/36), followed by internal carotid artery (25.0%=9/36). 47.2% of IAS exhibited % diameter stenosis ≥75%. Furthermore, 58.3% of HeFH patients with IAS exhibited concomitance of CAD, PAD or carotid stenosis. They were more likely to be older (Table). While there was no significant difference in LDL-C level, an elevated triglyceride level was observed in those with IAS (Table). Of note, during the observational period (median=14.1 years), IAS was associated with a greater likelihood of experiencing not only stroke but other cardiovascular events (all-cause death + ACS + PAD) (picture). Multivariate analysis demonstrated triglyceride level ≥1.7mmol/l as an independent predictor of IAS in HeFH patients (HR=5.53, 95% CI: 1.85–16.5, p=0.002).
Conclusions
Around one-fourth of HeFH patients harboured IAS, which was associated with concomitance of atherosclerosis in other vascular beds and the occurrence of stroke and other cardiovascular events. Given the relationship of IAS with hypertriglyceridemia, this lipid feature may be an important contributor to atherosclerotic formation which involves intracranial artery in HeFH patients.
Clinical outcome
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- S Funabashi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - Y Kataoka
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - M Hori
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - M Ogura
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - K Matsuki
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - T Doi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - T Noguchi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - M Harada-Shiba
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| |
Collapse
|
26
|
Choi J, Yoshie K, Moteki T, Ogura M. Parametric Study of Fixed-Bed Dehumidification Using a PCM-Containing Adsorbent for Effective Recovery of Heat of Adsorption. J Chem Eng Japan / JCEJ 2020. [DOI: 10.1252/jcej.20we087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Jihye Choi
- Department of Chemical System Engineering, The University of Tokyo
| | - Kenichi Yoshie
- Department of Chemical System Engineering, The University of Tokyo
| | | | - Masaru Ogura
- Institute of Industrial Science, The University of Tokyo
| |
Collapse
|
27
|
Zhu J, Osuga R, Ishikawa R, Shibata N, Ikuhara Y, Kondo JN, Ogura M, Yu J, Wakihara T, Liu Z, Okubo T. Ultrafast Encapsulation of Metal Nanoclusters into MFI Zeolite in the Course of Its Crystallization: Catalytic Application for Propane Dehydrogenation. Angew Chem Int Ed Engl 2020; 59:19669-19674. [PMID: 32602591 DOI: 10.1002/anie.202007044] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Indexed: 11/07/2022]
Abstract
Encapsulating metal nanoclusters into zeolites combines the superior catalytic activity of the nanoclusters with high stability and unique shape selectivity of the crystalline microporous materials. The preparation of such bifunctional catalysts, however, is often restricted by the mismatching in time scale between the fast formation of nanoclusters and the slow crystallization of zeolites. We herein demonstrate a novel strategy to overcome the mismatching issue, in which the crystallization of zeolites is expedited so as to synchronize it with the rapid formation of nanoclusters. The concept was demonstrated by confining Pt and Sn nanoclusters into a ZSM-5 (MFI) zeolite in the course of its crystallization, leading to an ultrafast, in situ encapsulation within just 5 min. The Pt/Sn-ZSM-5 exhibited exceptional activity and selectivity with stability in the dehydrogenation of propane to propene. This method of ultrafast encapsulation opens up a new avenue for designing and synthesizing composite zeolitic materials with structural and compositional complexity.
Collapse
Affiliation(s)
- Jie Zhu
- Department of Chemical System Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan
| | - Ryota Osuga
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259-R1-10 Nagatsuta, Midori-ku, Yokohama, 226-8503, Japan
| | - Ryo Ishikawa
- Institute of Engineering Innovation, The University of Tokyo, 2-11-16 Yayoi, Bunkyo-ku, Tokyo, 113-8656, Japan.,PRESTO (Japan) Science and Technology Agency, Kawaguchi, Saitama, 332-0012, Japan
| | - Naoya Shibata
- Institute of Engineering Innovation, The University of Tokyo, 2-11-16 Yayoi, Bunkyo-ku, Tokyo, 113-8656, Japan
| | - Yuichi Ikuhara
- Institute of Engineering Innovation, The University of Tokyo, 2-11-16 Yayoi, Bunkyo-ku, Tokyo, 113-8656, Japan
| | - Junko N Kondo
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259-R1-10 Nagatsuta, Midori-ku, Yokohama, 226-8503, Japan
| | - Masaru Ogura
- Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8505, Japan
| | - Jihong Yu
- State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, International Center of Future Science, Jilin University, 2699 Qianjin Street, Changchun, 130012, China
| | - Toru Wakihara
- Department of Chemical System Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.,Institute of Engineering Innovation, The University of Tokyo, 2-11-16 Yayoi, Bunkyo-ku, Tokyo, 113-8656, Japan
| | - Zhendong Liu
- Department of Chemical System Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan
| | - Tatsuya Okubo
- Department of Chemical System Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan
| |
Collapse
|
28
|
Zhu J, Osuga R, Ishikawa R, Shibata N, Ikuhara Y, Kondo JN, Ogura M, Yu J, Wakihara T, Liu Z, Okubo T. Ultrafast Encapsulation of Metal Nanoclusters into MFI Zeolite in the Course of Its Crystallization: Catalytic Application for Propane Dehydrogenation. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202007044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Jie Zhu
- Department of Chemical System Engineering The University of Tokyo 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8656 Japan
| | - Ryota Osuga
- Laboratory for Chemistry and Life Science, Institute of Innovative Research Tokyo Institute of Technology 4259-R1-10 Nagatsuta, Midori-ku Yokohama 226-8503 Japan
| | - Ryo Ishikawa
- Institute of Engineering Innovation The University of Tokyo 2-11-16 Yayoi, Bunkyo-ku Tokyo 113-8656 Japan
- PRESTO (Japan) Science and Technology Agency Kawaguchi Saitama 332-0012 Japan
| | - Naoya Shibata
- Institute of Engineering Innovation The University of Tokyo 2-11-16 Yayoi, Bunkyo-ku Tokyo 113-8656 Japan
| | - Yuichi Ikuhara
- Institute of Engineering Innovation The University of Tokyo 2-11-16 Yayoi, Bunkyo-ku Tokyo 113-8656 Japan
| | - Junko N. Kondo
- Laboratory for Chemistry and Life Science, Institute of Innovative Research Tokyo Institute of Technology 4259-R1-10 Nagatsuta, Midori-ku Yokohama 226-8503 Japan
| | - Masaru Ogura
- Institute of Industrial Science The University of Tokyo 4-6-1 Komaba, Meguro-ku Tokyo 153-8505 Japan
| | - Jihong Yu
- State Key Laboratory of Inorganic Synthesis and Preparative Chemistry College of Chemistry, International Center of Future Science Jilin University 2699 Qianjin Street Changchun 130012 China
| | - Toru Wakihara
- Department of Chemical System Engineering The University of Tokyo 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8656 Japan
- Institute of Engineering Innovation The University of Tokyo 2-11-16 Yayoi, Bunkyo-ku Tokyo 113-8656 Japan
| | - Zhendong Liu
- Department of Chemical System Engineering The University of Tokyo 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8656 Japan
| | - Tatsuya Okubo
- Department of Chemical System Engineering The University of Tokyo 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8656 Japan
| |
Collapse
|
29
|
Affiliation(s)
- Jihye Choi
- Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan
| | - Masaru Ogura
- Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan
| |
Collapse
|
30
|
Moteki T, Tominaga N, Ogura M. CO‐Assisted Direct Methane Conversion into C
1
and C
2
Oxygenates over ZSM‐5 Supported Transition and Platinum Group Metal Catalysts Using Oxygen as an Oxidant. ChemCatChem 2020. [DOI: 10.1002/cctc.202000168] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Takahiko Moteki
- Institute of Industrial ScienceThe University of Tokyo 4-6-1 Komaba Meguro-ku Tokyo 153-8505 Japan
| | - Naoto Tominaga
- Institute of Industrial ScienceThe University of Tokyo 4-6-1 Komaba Meguro-ku Tokyo 153-8505 Japan
| | - Masaru Ogura
- Institute of Industrial ScienceThe University of Tokyo 4-6-1 Komaba Meguro-ku Tokyo 153-8505 Japan
| |
Collapse
|
31
|
Kubota H, Liu C, Toyao T, Maeno Z, Ogura M, Nakazawa N, Inagaki S, Kubota Y, Shimizu KI. Formation and Reactions of NH4NO3 during Transient and Steady-State NH3-SCR of NOx over H-AFX Zeolites: Spectroscopic and Theoretical Studies. ACS Catal 2020. [DOI: 10.1021/acscatal.9b05151] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Hiroe Kubota
- Institute for Catalysis, Hokkaido University, N-21, W-10, Sapporo 001-0021, Japan
| | - Chong Liu
- Institute for Catalysis, Hokkaido University, N-21, W-10, Sapporo 001-0021, Japan
| | - Takashi Toyao
- Institute for Catalysis, Hokkaido University, N-21, W-10, Sapporo 001-0021, Japan
- Elements Strategy Initiative for Catalysts and Batteries, Kyoto University, Katsura, Kyoto 615-8520, Japan
| | - Zen Maeno
- Institute for Catalysis, Hokkaido University, N-21, W-10, Sapporo 001-0021, Japan
| | - Masaru Ogura
- Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan
| | - Naoto Nakazawa
- Division of Materials Science and Chemical Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
| | - Satoshi Inagaki
- Division of Materials Science and Chemical Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
| | - Yoshihiro Kubota
- Division of Materials Science and Chemical Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
| | - Ken-ichi Shimizu
- Institute for Catalysis, Hokkaido University, N-21, W-10, Sapporo 001-0021, Japan
- Elements Strategy Initiative for Catalysts and Batteries, Kyoto University, Katsura, Kyoto 615-8520, Japan
| |
Collapse
|
32
|
Ohata Y, Nishitoba T, Yokoi T, Moteki T, Ogura M. Effect of Zeolite Topology on Cu Active Site Formation for NO Direct Decomposition. BCSJ 2019. [DOI: 10.1246/bcsj.20190216] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Yusuke Ohata
- Institute of Industrial Science, The University of Tokyo, Komaba, Meguro-ku, Tokyo 153-8505, Japan
| | - Toshiki Nishitoba
- Chemical Resources Laboratory, Tokyo Institute of Technology, Nagatsuta, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Toshiyuki Yokoi
- Chemical Resources Laboratory, Tokyo Institute of Technology, Nagatsuta, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
- PRESTO, JST, Nagatsuta, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Takahiko Moteki
- Institute of Industrial Science, The University of Tokyo, Komaba, Meguro-ku, Tokyo 153-8505, Japan
- Unit of Elements Strategy Initiative for Catalysts & Batteries, Kyoto University, Katsura, Nishikyo, Kyoto 615-8510, Japan
| | - Masaru Ogura
- Institute of Industrial Science, The University of Tokyo, Komaba, Meguro-ku, Tokyo 153-8505, Japan
- Unit of Elements Strategy Initiative for Catalysts & Batteries, Kyoto University, Katsura, Nishikyo, Kyoto 615-8510, Japan
| |
Collapse
|
33
|
Funabashi S, Kataoka Y, Harada-Shiba M, Hori M, Doi T, Ogura M, Hirayama A, Nishikawa R, Tsuda K, Noguchi T, Yasuda S. P938Extensive formation of atherosclerotic cardiovascular disease in subjects with severe familial hypercholesterolemia defined by the international atherosclerosis society criteria. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
The International Atherosclerosis Society (IAS) has proposed “severe familial hypercholesterolemia (FH)” as a FH phenotype with the highest cardiovascular risk. Coronary artery disease (CAD) represents a major atherosclerotic change in FH patients. Given their higher LDL-C level and atherogenic clinical features, more extensive formation of atherosclerosis cardiovascular disease including not only CAD but stroke/peripheral artery disease (PAD) may more frequently occur in severe FH.
Methods
481 clinically-diagnosed heterozygous FH subjects were analyzed. Severe FH was defined as untreated LDL-C>10.3 mmol/l, LDL-C>8.0 mmol/l+ 1 high-risk feature, LDL-C>4.9 mmol/l + 2 high-risk features or presence of clinical ASCVD according to IAS proposed statement. Cardiac (cardiac death and ACS) and non-cardiac (stroke and peripheral artery disease) events were compared in severe and non-severe FH subjects.
Results
Severe FH was identified in 50.1% of study subjects. They exhibit increased levels of LDL-C and Lipoprotein (a) with a higher frequency of LDLR mutation. Furthermore, a proportion of %LDL-C reduction>50% was greater in severe FH under more lipid-lowering therapy (Table). However, during the observational period (median=6.3 years), severe FH was associated with a 5.9-fold (95% CI, 2.05–25.2; p=0.004) and 5.8-fold (95% CI, 2.02–24.7; p=0.004) greater likelihood of experiencing cardiac-death/ACS and stroke/PAD, respectively (picture). Multivariate analysis demonstrated severe FH as an independent predictor of both cardiac-death/ACS (hazard ratio=3.39, 95% CI=1.12–14.7, p=0.02) and stroke/PAD (hazard ratio=3.38, 95% CI=1.16–14.3, p=0.02) events.
Clinical characteristics of severe FH Non-severe FH Severe FH P-value Baseline LDL-C (mmol/l) 5.3±1.5 6.6±2.0 <0.0001 Lp(a) (mg/dl) 15 [8–28] 21 [10–49] <0.0001 LDLR mutation (%) 49.6% 58.9% 0.00398 On-treatment LDL-C (mmol) 133 [106–165] 135 [103–169] 0.9856 %LDL-C reduction>50% 21.3% 49.8% <0.0001 High-intensity statin (%) 13.3% 42.3% <0.0001 PCSK9 inhibitor (%) 6.3% 21.2% <0.0001
Clinical outcome
Conclusions
Severe FH subjects exhibit substantial atherosclerotic risks for coronary, carotid and peripheral arteries despite lipid lowering therapy. Our finding underscore the screening of systemic arteries and the adoption of further stringent lipid management in severe FH patients.
Collapse
Affiliation(s)
- S Funabashi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - Y Kataoka
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - M Harada-Shiba
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - M Hori
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - T Doi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - M Ogura
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - A Hirayama
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - R Nishikawa
- Sapporo Medical University, Renal and Metabolic Medicine, Sapporo, Japan
| | - K Tsuda
- Osaka Medical College, Cardiology, Takatsuki, Japan
| | - T Noguchi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - S Yasuda
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| |
Collapse
|
34
|
Shibata G, Eijima W, Koiwai R, Shimizu KI, Nakasaka Y, Kobashi Y, Kubota Y, Ogura M, Kusaka J. NH3-SCR by monolithic Cu-ZSM-5 and Cu-AFX catalysts: Kinetic modeling and engine bench tests. Catal Today 2019. [DOI: 10.1016/j.cattod.2018.06.023] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
35
|
Ogura M, Ohmachi K, Suzuki R, Atsuta Y, Ito T, Ohyashiki K, Yano S, Hidaka M, Ando K, Fukuhara N, Morishita Y, Suzuki T, Tsukasaki K, Kobayashi N, Tsukamoto K, Ozawa Y, Yamamoto K, Hotta T, Kinoshita T. A PHASE II STUDY OF THP (PIRARUBICIN)-COP THERAPY IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED PTCL: THP-3 STUDY OF JAPAN HEMATOPOIETIC MALIGNANCY CLINICAL STUDY GROUP. Hematol Oncol 2019. [DOI: 10.1002/hon.147_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Ogura
- Hematology and Oncology/Hematology and Oncology; Kasugai Municipal Hospital/Nagoya Daini Red Cross Hospital; Kasugai/Nagoya Japan
| | - K. Ohmachi
- Hematology and Oncology; Tokai University School of Medicine; Isehara Japan
| | - R. Suzuki
- Oncology and Hematology; Shimane University Hospital; Izumo Japan
| | - Y. Atsuta
- Data Center; Japanese Data Center for Hematopoietic Cell Transplantation; Nagoya Japan
| | - T. Ito
- Hematology and Oncology; Anjyo Kosei Hospital; Anjo Japan
| | - K. Ohyashiki
- Hematology; Tokyo Medical University; Tokyo Japan
| | - S. Yano
- Clinical Oncology and Hematology; Jikei University School of Medicine; Tokyo Japan
| | - M. Hidaka
- Hematology; National Hospital Organization; Kumamoto Japan
| | - K. Ando
- Hematology and Oncology; Tokai University School of Medicine; Isehara Japan
| | - N. Fukuhara
- Hematology and Rheumatology; Tohoku University Hospital; Sendai Japan
| | - Y. Morishita
- Hematology and Oncology; Konan Kosei Hospital; Konan Japan
| | - T. Suzuki
- Hematology; Shiga Medical Center for Adults; Moriyama Japan
| | - K. Tsukasaki
- Hematology; Nagasaki University Hospital; Nagasaki Japan
| | - N. Kobayashi
- Hematology; Sapporo Hokuyu Hospital; Sapporo Japan
| | - K. Tsukamoto
- Medicine and Clinical Science; Gunma University Graduate School of Medicine; Maebashi Japan
| | - Y. Ozawa
- Hematology; Japanese Red Cross Nagoya First Hospital; Nagoya Japan
| | - K. Yamamoto
- Hematology and Cell Therapy; Aichi Cancer Center; Nagoya Japan
| | - T. Hotta
- President; Nagoya Medical Center; Nagoya Japan
| | - T. Kinoshita
- Hematology and Cell Therapy; Aichi Cancer Center; Nagoya Japan
| |
Collapse
|
36
|
Choi J, Yoshie K, Moteki T, Ogura M. Theoretical Evaluation of an Organic Phase Change Material (PCM)-Inserted Dual-Functional Adsorbent for the Recovery of Heat of Adsorption. Ind Eng Chem Res 2019. [DOI: 10.1021/acs.iecr.9b00198] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jihye Choi
- Department of Chemical System Engineering, The University of Tokyo, 113-8656 Tokyo, Japan
| | - Kenichi Yoshie
- Department of Chemical System Engineering, The University of Tokyo, 113-8656 Tokyo, Japan
| | - Takahiko Moteki
- Institute of Industrial Science, The University of Tokyo, Komaba, 153-8505 Tokyo, Japan
| | - Masaru Ogura
- Institute of Industrial Science, The University of Tokyo, Komaba, 153-8505 Tokyo, Japan
| |
Collapse
|
37
|
Mutai T, Muramatsu T, Yoshikawa I, Houjou H, Ogura M. Development of Imidazo[1,2-a]pyridine Derivatives with an Intramolecular Hydrogen-Bonded Seven-Membered Ring Exhibiting Bright ESIPT Luminescence in the Solid State. Org Lett 2019; 21:2143-2146. [DOI: 10.1021/acs.orglett.9b00455] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Toshiki Mutai
- Department of Materials and Environmental Science, Institute of Industrial Science, The University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo 153-8505, Japan
| | - Tatsuya Muramatsu
- Department of Materials and Environmental Science, Institute of Industrial Science, The University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo 153-8505, Japan
| | - Isao Yoshikawa
- Department of Materials and Environmental Science, Institute of Industrial Science, The University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo 153-8505, Japan
| | - Hirohiko Houjou
- Department of Materials and Environmental Science, Institute of Industrial Science, The University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo 153-8505, Japan
| | - Masaru Ogura
- Department of Materials and Environmental Science, Institute of Industrial Science, The University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo 153-8505, Japan
| |
Collapse
|
38
|
Kiuchi Z, Ogura M, Sato M, Kamei K, Ishikura K, Abe J, Ito S. No preventive or therapeutic efficacy of infliximab against macrophage activation syndrome due to systemic juvenile idiopathic arthritis. Scand J Rheumatol 2018; 48:246-248. [PMID: 30406708 DOI: 10.1080/03009742.2018.1493745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Z Kiuchi
- a Department of Nephrology and Rheumatology , National Center for Child Health and Development , Tokyo , Japan.,b Department of Paediatrics , Kyorin University School of Medicine , Tokyo , Japan
| | - M Ogura
- a Department of Nephrology and Rheumatology , National Center for Child Health and Development , Tokyo , Japan
| | - M Sato
- a Department of Nephrology and Rheumatology , National Center for Child Health and Development , Tokyo , Japan
| | - K Kamei
- a Department of Nephrology and Rheumatology , National Center for Child Health and Development , Tokyo , Japan
| | - K Ishikura
- a Department of Nephrology and Rheumatology , National Center for Child Health and Development , Tokyo , Japan
| | - J Abe
- c Department of Allergy and Immunology , National Center for Child Health and Development , Tokyo , Japan
| | - S Ito
- a Department of Nephrology and Rheumatology , National Center for Child Health and Development , Tokyo , Japan.,d Department of Paediatrics, Graduate School of Medicine , Yokohama City University , Kanagawa , Japan
| |
Collapse
|
39
|
Kozuki R, Shinozaki E, Osumi H, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Suzuki T, Ota Y, Nakayama I, Takahari D, Chin K, Nagasaki T, Akiyoshi T, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno M, Yamaguchi K. A retrospective analysis of the association between perioperative carcinoembryonic antigen level and prognosis in stage III colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Suenaga M, Wakatsuki T, Ogura M, Ichimura T, Shinozaki E, Nakayama I, Osumi H, Ota Y, Chin K, Mashima T, Seimiya H, Takahari D, Yamaguchi K. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Takahashi R, Wakatsuki T, Yamamoto N, Taguchi S, Shinozaki E, Osumi H, Ogura M, Ichimura T, Takahari D, Suenaga M, Chin K, Oguchi M, Ueno M, Yamaguchi K. p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Osumi H, Shinozaki E, Zembutsu H, Takeda Y, Wakatsuki T, Ichimura T, Ota Y, Nakayama I, Ogura M, Suenaga M, Takahari D, Chin K, Saiura A, Takahashi S, Noda T, Yamaguchi K. Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Hori M, Ohta N, Masuda H, Son C, Hosoda K, Ogura M, Miyamoto Y, Harada-shiba M. The frequency and the spectrum of causative mutations in Japanese familial hypercholesterolemia heterozygotes. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Takahashi Y, Kawakami M, Noda T, Okada K, Tsujimoto K, Nakamura T, Okuyama K, Ogura M, Haruyama K, Teramae T, Morimoto J, Liu M. The effect of an exoskeleton robot on genu recurvatum during gait in patients with chronic stroke: A feasibility study. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Okuyama K, Kawakami M, Ogura M, Takasaki K, Liu F, Noda T, Tanabe S, Yamaguchi T, Ushiba J, Liu M. Stepwise intervention for proximal and distal upper extremity motor function in patients with chronic stroke: A report of 2 cases. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
46
|
Osumi H, Shinozaki E, Chin K, Takahari D, Ogura M, Ichimura T, Wakatsuki T, Ota Y, Nakayama I, Suenaga M, Yamaguchi K. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Osumi H, Shinozaki E, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Ota Y, Nakayama I, Takahari D, Chin K, Yamaguchi K. Is the PEG-G-CSF useful as the prevention for the severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Osumi H, Takahari D, Chin K, Ogura M, Ichimura T, Wakatsuki T, Nakayama I, Ota Y, Suenaga M, Shinozaki E, Yamaguchi K. First‐line mFOLFOX6 for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Saida K, Kamei K, Ogura M, Matsumura S, Kano Y, Sato M, Andoh A, Ishikura K. Azathioprine-induced Agranulocytosis and Severe Alopecia After Kidney Transplantation Associated With a NUDT15 Polymorphism: A Case Report. Transplant Proc 2018; 50:3925-3927. [PMID: 30577288 DOI: 10.1016/j.transproceed.2018.04.039] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 04/12/2018] [Indexed: 01/17/2023]
Abstract
BACKGROUND Azathioprine (AZA) is the drug recommended for the continuation of immunosuppressive treatment after renal transplant in women during pregnancy. CASE REPORT A 37-year-old Japanese female developed agranulocytosis and severe alopecia after initiation of AZA (50 mg), used as an alternative to mycophenolate mofetil (MMF, 1000 mg) therapy in anticipation of a planned pregnancy. Within 4 days of the initiation of AZA therapy, the patient developed a high fever, leucopenia, and cranial alopecia. Genetic testing revealed a homozygous polymorphism of NUDT15 (rs116855232, NM_018283.3:c.415C>T: p.Arg139Cys), which has previously been identified as a risk factor for AZA-related complications in patients with inflammatory bowel disease. CONCLUSION Genetic screening for NUDT15 could contribute to the prevention of serious adverse reactions to AZA and provide the opportunity for personalized medicine. Identification of a safe alternative to MMF during pregnancy after a renal transplant is a problem to be resolved in the future.
Collapse
Affiliation(s)
- K Saida
- Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
| | - K Kamei
- Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
| | - M Ogura
- Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
| | - S Matsumura
- Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
| | - Y Kano
- Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
| | - M Sato
- Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
| | - A Andoh
- Department of Medicine, Shiga University of Medical Science, Shiga, Japan
| | - K Ishikura
- Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
| |
Collapse
|
50
|
Kishi N, Ogura M. EP-1402: Prognostic value of hematological inflammatory markers in patients with non-small cell lung cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31711-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|